News

According to the company, the grant funding from the Choroideremia Research Foundation is in support of validating functional vision assessments for patients with profound blindness.

The molecule is being evaluated in 2 phase 3 clinical trials for wet AMD and is administered via intravitreal injection in combination with standard-of-care anti–VEGF-A therapy.

The LYNX-2 Phase 3 study is evaluating phentolamine ophthalmic solution 0.75% for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery

Scientists at the National Institutes of Health use artificial intelligence called ‘P-GAN’ to improve next-generation imaging of cells in the back of the eye.

VG901 is designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in patients diagnosed with retinitis pigmentosa.

The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease

Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment on macular degeneration-treated mice in space.

Authors explained that Nfe2l gene family members -1, -2, and -3 mediate the cellular response to oxidative stress, including in the CNS

Neda Nikpoor, MD, shares highlights from her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Paul Harasymowycz, MD, details his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma" from this year's ASCRS meeting in Boston, Massachusetts.

Results showed LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, while LNZ101 showed similar results but ultimately failed to show superiority to LNZ100.

William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.

Anthony Wallace, US Surgical vice president and general manager for Bausch + Lomb, reviews the latest advancements and updates in an interview with Ophthalmology Times.

Dan Tran, MD, shares key takeaways from his presentation, including a grading scale for incisions created with femtosecond laser.

OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery, while topline readout from the second Phase 3 OPTIMIZE-2 is anticipated later this year to support an NDA submission.

Rahul S Tonk, MD, MBA, sat down to discuss a roundtable discussion he had on DMEK and DSEK surgery at this year's ASCRS meeting held in Boston, Massachusetts, from Friday, April 5, to Monday, April 8, 2024.

Alejandro Espaillat, MD, sat down to discuss his presentation on pearls for the anterior segment surgeon at this year's ASCRS meeting held in Boston, Massachusetts.

Results of the study indicated that systemic treatment led to elevations in liver function test results, with some patients experiencing values twice as high as normal.

Contrary to the traditional understanding that this disorder remains stable, long-term structural changes were observed through spectral-domain optical coherence tomography (SD-OCT) imaging.

Investigators wanted to determine why patients who have retinal diseases such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) can undergo cataract surgeries without experiencing a worsening of their retinal disease, while some patients do.

Mark J. Gallardo, MD, highlighted the results from a phase 2 clinical trial of a travoprost intracameral implant in open-angle glaucoma or ocular hypertension.

Researchers conducted a retrospective chart review spanning from January 2015 to January 2021 to compare the incidence rates of infectious keratitis before and during the pandemic among PRK patients.

According to the companies, the tool is affordable, portable, scalable, and intentionally designed to train surgeons in low- and middle-income countries, home to 9 out of 10 people with vision loss due to the difficulty of accessing eye care. The VR tool is being unveiled at the American Society of Cataract and Refractive Surgery Annual Meeting in Boston.

Authors reported that increasing the number of intense pulsed light (IPL) sessions is beneficial for patients with moderate-to-severe meibomian gland dysfunction (MGD) to increase the response rate of treatment.

The technology uses a superelastic, memory-shaped nitinol guide that facilitates up to 360-degree guided circumferential removal of the trabecular meshwork.